ATE321548T1 - Verwendung von statin zur behandlung von hauterkrankungen - Google Patents

Verwendung von statin zur behandlung von hauterkrankungen

Info

Publication number
ATE321548T1
ATE321548T1 AT95934980T AT95934980T ATE321548T1 AT E321548 T1 ATE321548 T1 AT E321548T1 AT 95934980 T AT95934980 T AT 95934980T AT 95934980 T AT95934980 T AT 95934980T AT E321548 T1 ATE321548 T1 AT E321548T1
Authority
AT
Austria
Prior art keywords
statin
skin diseases
treat skin
treat
alleviation
Prior art date
Application number
AT95934980T
Other languages
English (en)
Inventor
Naphtali Savion
Sara Brenner
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE321548T1 publication Critical patent/ATE321548T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95934980T 1994-09-13 1995-09-13 Verwendung von statin zur behandlung von hauterkrankungen ATE321548T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11094394A IL110943A (en) 1994-09-13 1994-09-13 Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders

Publications (1)

Publication Number Publication Date
ATE321548T1 true ATE321548T1 (de) 2006-04-15

Family

ID=11066547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95934980T ATE321548T1 (de) 1994-09-13 1995-09-13 Verwendung von statin zur behandlung von hauterkrankungen

Country Status (14)

Country Link
US (1) US6126947A (de)
EP (1) EP0793489B9 (de)
JP (1) JP4128616B2 (de)
KR (1) KR970705990A (de)
CN (1) CN1106841C (de)
AT (1) ATE321548T1 (de)
AU (1) AU694274B2 (de)
BR (1) BR9509006A (de)
CA (1) CA2199844C (de)
DE (1) DE69534908T2 (de)
IL (1) IL110943A (de)
MX (1) MXPA97001884A (de)
RU (1) RU2159611C2 (de)
WO (1) WO1996008248A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738510A3 (de) * 1995-04-20 2005-12-21 L'oreal Verwendung eines HMG-CoA-Reduktase Inhibitors als Hautalterungschutzmittel und als Anti-Aknemittel. Zusammensetzung enthaltend mindestens einen HMG-CoA-Reduktase Inhibitor und mindestens einen Wirkstoff mit abschuppenden Eigenschaften
US5840752A (en) * 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
FI972040A (fi) * 1997-05-13 1998-11-14 Nokia Telecommunications Oy Menetelmä pakettivälitteiseen tiedonsiirtoon
WO1999056545A1 (en) * 1998-05-05 1999-11-11 Anwel Saqib R Hair and skin treatment method and composition
FR2801508B1 (fr) * 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6699886B2 (en) * 2001-05-31 2004-03-02 Cellegy Pharmaceuticals, Inc. Store operated calcium influx inhibitors and methods of use
US7060729B2 (en) * 2002-09-05 2006-06-13 Reza Babapour Composition and method for treating skin
WO2004026297A1 (ja) * 2002-09-20 2004-04-01 Kowa Co., Ltd. 外用剤
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
DK1656026T3 (da) 2003-08-22 2014-07-14 Dupont Nutrition Biosci Aps Sammensætning, der omfatter et bakteriocin og et ekstrakt fra en plante fra læbeblomstfamilien
KR20060135826A (ko) * 2004-03-31 2006-12-29 코와 가부시키가이샤 외용제
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
GB2459922A (en) * 2008-05-13 2009-11-18 Univ Dundee Treatment for keratinizing dermatological disorders by reduction in keratin expression
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
US20120149775A1 (en) * 2010-11-29 2012-06-14 Shiseido Company, Ltd. Methods for preventing and improving skin elastic property loss
US9273192B1 (en) * 2014-11-06 2016-03-01 George Reck Method of preventing microbial growth on water treatment dispersant
WO2017059389A1 (en) * 2015-10-01 2017-04-06 Kythera Biopharmaceuticals, Inc. Compositions comprising a statin for use in methods of adipolysis
MX2019004579A (es) 2016-10-24 2019-08-21 Colgate Palmolive Co Composiciones para el cuidado bucal y metodos de uso.
JP2022036341A (ja) * 2018-10-12 2022-03-08 学校法人慶應義塾 慢性皮膚炎の治療のための医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047235A (de) * 1963-09-09
GB1026927A (en) * 1964-01-20 1966-04-20 Richardson Merrell Inc Triphenylhaloethylenes
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
GB2081580A (en) * 1980-08-07 1982-02-24 Anand Chaman Lal Sapindus trifoliatus extracts
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
US5466687A (en) * 1992-10-22 1995-11-14 Dr. Karl Thomae Gmbh Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation
DE4303840A1 (de) * 1992-10-22 1994-08-11 Thomae Gmbh Dr K Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
DE4239151A1 (de) * 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
US5730992A (en) * 1994-09-13 1998-03-24 Ramot University Authority For Applied Research And Industrial Development, Ltd. Compositions for the treatment of skin disorders

Also Published As

Publication number Publication date
KR970705990A (ko) 1997-11-03
JPH10505838A (ja) 1998-06-09
DE69534908D1 (de) 2006-05-18
EP0793489A4 (de) 2001-12-19
AU3717395A (en) 1996-03-29
CA2199844A1 (en) 1996-03-21
MXPA97001884A (es) 2004-04-16
IL110943A (en) 1997-02-18
BR9509006A (pt) 1998-06-23
RU2159611C2 (ru) 2000-11-27
WO1996008248A1 (en) 1996-03-21
EP0793489B1 (de) 2006-03-29
CA2199844C (en) 2007-04-10
CN1158567A (zh) 1997-09-03
CN1106841C (zh) 2003-04-30
US6126947A (en) 2000-10-03
AU694274B2 (en) 1998-07-16
EP0793489B9 (de) 2006-08-30
DE69534908T2 (de) 2007-01-25
IL110943A0 (en) 1994-11-28
EP0793489A1 (de) 1997-09-10
JP4128616B2 (ja) 2008-07-30

Similar Documents

Publication Publication Date Title
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69623325T2 (de) 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
WO1996001430A3 (en) Screening for nuc inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties